4-Bromobenzyl bromide → 3-[(4-Bromophenyl)methyl]-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
反応式
Cl.[CH2:2]([C:6]1[NH:10][C:9](=[O:11])[C:8]2([CH2:15][CH2:14][CH2:13][CH2:12]2)[N:7]=1)[CH2:3][CH2:4][CH3:5].[Br:16][C:17]1[CH:24]=[CH:23][C:20]([CH2:21]Br)=[CH:19][CH:18]=1>>[Br:16][C:17]1[CH:24]=[CH:23][C:20]([CH2:21][N:10]2[C:9](=[O:11])[C:8]3([CH2:15][CH2:14][CH2:13][CH2:12]3)[N:7]=[C:6]2[CH2:2][CH2:3][CH2:4][CH3:5])=[CH:19][CH:18]=1参加物
3
実験手順
In this application further describes another process comprising the steps of reacting 2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one monohydrochloride (A) with 4-bromobenzyl bromide (B) in presence of base and solvent to give 3-[4-bromobenzyl]-2-butyl-1,3-diazaspiro[4,4]non-1-en-4-one (C) which is condensed with 2-[2′-(triphenylmethyl-2′H-tetrazol-5′-yl)phenyl boronic acid in the presence of tetrakis triphenyl phosphine palladium and base to give Irbesartan (I).
出典と根拠
- ORDレコード
- ord-5925a54fd7c14b39ae84cee5567821e7
- 出典データセット
- uspto-grants-2010_01
- 特許番号
- US07652147B2
反応ノート
読み込み中…